Nrf2 activators as attractive therapeutics for diabetic nephropathy.
Diabetic Complications Division, Oxidative Stress Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. judy.dehaan@bakeridi.edu.au
Judy B
JB
de Haan
D000171:Acrolein / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D006801:Humans; D017879:Isothiocyanates; D051267:NF-E2-Related Factor 2 / Q000819:agonists*; D013454:Sulfoxides; D013861:Thiocyanates / Q000627:therapeutic use*
D017879:Isothiocyanates; D051267:NF-E2-Related Factor 2; D013454:Sulfoxides; D013861:Thiocyanates; D000171:Acrolein; C016766:sulforaphane; C012843:cinnamaldehyde